Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#161 / 167 Total
UFI - UNIFI, Inc. - Stock Price Chart
TickerUFI [NYSE]
CompanyUNIFI, Inc.
CountryUSA
IndustryTextile Manufacturing
Market Cap100.79MEPS (ttm)-2.96
P/E-EPS this Y6.55%
Forward P/E8.67EPS next Y129.91%
PEG-EPS past 5Y-
P/S0.17EPS next 5Y10.00%
P/B0.35EPS Q/Q-9.57%
Dividend-Sales Q/Q0.52%
Insider Own22.07%Inst Own56.41%
Insider Trans7.11%Inst Trans-8.49%
Short Float2.03%EarningsMay 08/a
Analyst Recom3.00Target Price12.50
Avg Volume72.19K52W Range5.54 - 9.34
Unifi, Inc. engages in the manufacture and sale of synthetic and recycled products made from polyester and nylon. It operates through the following geographical segments: Americas, Brazil, and Asia. The Americas segment sells recycled and synthetic products to yarn manufacturers, knitters and weavers that produce yarn and/or fabric for the apparel, hosiery, home furnishings, automotive, industrial, medical, and other end-use markets principally in North and Central America. The Brazil segment is involved in the recycled and synthetic products to knitters and weavers that produce fabric for the apparel, home furnishings, automotive, industrial, and other end-use markets principally in Brazil. The Asia segment focuses on synthetic products for yarn manufacturers, knitters and weavers that produce fabric for apparel, home furnishings, automotive, industrial, and other end-use markets principally in Asia and Europe. The company was founded by George Allen Mebane IV in 1969 and is headquartered in Greensboro, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LANGONE KENNETH GDirectorDec 22 '23Buy5.75500,0002,875,0002,321,306Dec 27 04:05 PM
INCLUSIVE CAPITAL PARTNERS, L.10% OwnerNov 28 '23Sale6.52171,6421,118,2651,686,887Nov 29 05:12 PM
INCLUSIVE CAPITAL PARTNERS, L.10% OwnerNov 27 '23Sale6.7562,358420,8481,858,529Nov 29 05:12 PM
LANGONE KENNETH GDirectorSep 15 '23Buy7.033,00021,0901,806,402Sep 18 04:05 PM
LANGONE KENNETH GDirectorSep 14 '23Buy7.004,80033,6001,803,402Sep 18 04:05 PM
VREX - Varex Imaging Corp - Stock Price Chart
TickerVREX [NASD, RUT]
CompanyVarex Imaging Corp
CountryUSA
IndustryMedical Devices
Market Cap632.95MEPS (ttm)0.83
P/E18.70EPS this Y-46.65%
Forward P/E16.03EPS next Y43.54%
PEG3.74EPS past 5Y6.00%
P/S0.74EPS next 5Y5.00%
P/B1.11EPS Q/Q-66.40%
Dividend-Sales Q/Q-9.64%
Insider Own1.12%Inst Own105.96%
Insider Trans-1.95%Inst Trans-2.17%
Short Float11.30%EarningsMay 02/a
Analyst Recom1.50Target Price27.88
Avg Volume354.72K52W Range16.00 - 23.90
Varex Imaging Corp. engages in the design, manufacture, and sale of imaging components. It operates through the Medical and Industrial segments. The Medical segment delivers and services x-ray imaging components, including X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, and three-dimensional reconstruction software. The Industrial segment offers x-ray imaging products for use in security, and nondestructive testing and inspection applications. The company was founded in 2016 and is headquartered in Salt Lake City, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Honeysett Kimberley E.SVP and CLOMar 15 '24Sale17.372,86049,6782,853Mar 19 04:51 PM
Honeysett Kimberley E.SVP and General CounselNov 22 '23Sale19.726,174121,7510Nov 27 04:43 PM
Kunkel Jay K.DirectorMay 08 '23Sale21.909,120199,72811,598May 10 06:20 PM
KUKE - Kuke Music Holding Ltd ADR - Stock Price Chart
TickerKUKE [NYSE]
CompanyKuke Music Holding Ltd ADR
CountryChina
IndustryEntertainment
Market Cap56.65MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B8.13EPS Q/Q175.87%
Dividend-Sales Q/Q-41.84%
Insider Own-Inst Own0.02%
Insider Trans-Inst Trans-22.33%
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume58.60K52W Range0.42 - 3.50
Kuke Music Holding Ltd. is an investment holding company, which engages in the distribution of commercial copyrights, provision of music education solutions, sales of musical instruments, and provision of services related to music events and performances. It operates through the following business segments: Subscription, Licensing, and Smart Education, and Music Events and Performances. The Subscription, Licensing, and Smart Education segment distributes commercial copyrights and provision of music education solutions. The Music Events and Performances segment offers services related to music festival events and music performance and sale of Conch Smart Speakers. The company was founded by Yu He in 2007 and is headquartered in Beijing, China.
MNOV - Medicinova Inc - Stock Price Chart
TickerMNOV [NASD]
CompanyMedicinova Inc
CountryUSA
IndustryBiotechnology
Market Cap64.26MEPS (ttm)-0.17
P/E-EPS this Y-35.29%
Forward P/E-EPS next Y-4.35%
PEG-EPS past 5Y13.30%
P/S64.26EPS next 5Y20.00%
P/B1.03EPS Q/Q31.37%
Dividend-Sales Q/Q-
Insider Own5.24%Inst Own18.82%
Insider Trans0.00%Inst Trans-0.93%
Short Float0.53%EarningsFeb 16/b
Analyst Recom1.00Target Price16.50
Avg Volume49.34K52W Range1.26 - 2.66
Apr-02-24 07:00PM MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) (GlobeNewswire)
Mar-26-24 07:00PM MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan (GlobeNewswire)
Mar-20-24 07:00PM MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society (GlobeNewswire)
Mar-12-24 06:30AM MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology (GlobeNewswire)
Jan-17-24 06:00AM MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China (GlobeNewswire)
Dec-21-23 06:00PM MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology (GlobeNewswire)
Dec-06-23 06:00PM MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe (GlobeNewswire)
Nov-19-23 06:00PM MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology (GlobeNewswire)
Nov-10-23 09:57AM MediciNova: Q3 Earnings Snapshot (Associated Press Finance)
Oct-27-23 01:00AM MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria (GlobeNewswire)
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company was founded by Yuichi Iwaki on September 26, 2000, and is headquartered in La Jolla, CA.
ZVSA - ZyVersa Therapeutics Inc - Stock Price Chart
TickerZVSA [NASD]
CompanyZyVersa Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap4.14MEPS (ttm)-71.31
P/E-EPS this Y98.62%
Forward P/E-EPS next Y-206.98%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.20EPS Q/Q-6291.81%
Dividend-Sales Q/Q-
Insider Own1.17%Inst Own13.75%
Insider Trans0.00%Inst Trans-
Short Float0.61%EarningsMar 25/b
Analyst Recom1.00Target Price70.00
Avg Volume394.96K52W Range4.44 - 220.85
Apr-29-24 07:57AM ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease (GlobeNewswire) +15.63%
Apr-04-24 07:57AM ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes (GlobeNewswire)
Mar-25-24 08:17AM ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-18-24 07:57AM ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease (GlobeNewswire) +8.79%
Mar-14-24 07:57AM ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024 (GlobeNewswire)
Feb-29-24 07:57AM ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity (GlobeNewswire) +10.00%
Feb-28-24 07:57AM ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications (GlobeNewswire) -8.26%
Feb-26-24 07:55AM Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today? (InvestorPlace) +34.83%
Feb-22-24 07:47AM ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option (GlobeNewswire)
Feb-14-24 07:53AM ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases (GlobeNewswire)
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.
BEEM - Beam Global - Stock Price Chart
TickerBEEM [NASD]
CompanyBeam Global
CountryUSA
IndustrySolar
Market Cap90.23MEPS (ttm)-1.31
P/E-EPS this Y30.92%
Forward P/E-EPS next Y100.00%
PEG-EPS past 5Y48.72%
P/S1.34EPS next 5Y-
P/B1.80EPS Q/Q54.24%
Dividend-Sales Q/Q153.65%
Insider Own12.90%Inst Own19.34%
Insider Trans0.00%Inst Trans-10.70%
Short Float14.45%EarningsApr 17/a
Analyst Recom1.40Target Price17.75
Avg Volume103.56K52W Range5.00 - 13.66
Beam Global provides sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media. It develops, patents, designs, engineers and manufactures unique and advanced clean mobility solutions that protect the environment, save customers time and money, empower communities and keep people moving. The firm's core platforms include Beam EV ARC and Solar Tree sustainable EV charging systems, Beam AllCell high-performance energy storage solutions, energy resiliency and disaster preparedness products and a deep patent library. The company was founded by Robert Lane Noble on June 12, 2006 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WHEATLEY DESMOND CChief Executive OfficerOct 02 '23Sale7.356204,557100,929Oct 05 06:01 PM
WHEATLEY DESMOND CChief Executive OfficerJun 01 '23Sale11.811,40016,534101,549Jun 02 07:32 PM
ADIL - Adial Pharmaceuticals Inc - Stock Price Chart
TickerADIL [NASD]
CompanyAdial Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap6.89MEPS (ttm)-6.43
P/E-EPS this Y47.78%
Forward P/E-EPS next Y15.16%
PEG-EPS past 5Y38.36%
P/S-EPS next 5Y-
P/B0.69EPS Q/Q57.01%
Dividend-Sales Q/Q-
Insider Own6.78%Inst Own6.52%
Insider Trans0.00%Inst Trans-
Short Float26.71%EarningsNov 14/b
Analyst Recom1.67Target Price7.50
Avg Volume6.54M52W Range0.76 - 14.00
Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schuyler KevinDirectorSep 29 '23Buy2.747001,918700Oct 03 08:54 AM
110121314151617